MARKET

RDY

RDY

Dr.Reddys
NYSE

Real-time Quotes | Nasdaq Last Sale

65.56
-0.25
-0.38%
Opening 14:46 09/22 EDT
OPEN
66.00
PREV CLOSE
65.81
HIGH
66.00
LOW
65.56
VOLUME
18.54K
TURNOVER
--
52 WEEK HIGH
75.50
52 WEEK LOW
57.54
MARKET CAP
10.87B
P/E (TTM)
47.44
1D
5D
1M
3M
1Y
5Y
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr.
Benzinga · 09/10 14:21
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO
NEW YORK and SYDNEY, Australia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug deve...
GlobeNewswire · 09/09 12:30
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
Zacks.com · 09/08 15:34
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
Zacks.com · 09/07 14:08
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE: RD...
PR Newswire · 09/07 11:30
Citius Pharmaceuticals Acquires Rights to Oncology Immunotherapy E7777 From Dr. Reddy's Laboratories; Shares Rise Early
MT Newswires · 09/07 10:14
Dr. Reddy's Sells Rights to Oncology Drug to Citius Pharmaceuticals
MT Newswires · 09/07 05:07
BRIEF-Dr. Reddy's Laboratories Enters Into Definitive Agreement With Citius Pharmaceuticals To Sell Its Rights To Anti-Cancer Agent E7777 (Denileukin Diftitox)
reuters.com · 09/04 05:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDY. Analyze the recent business situations of Dr.Reddys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDY stock price target is 77.85 with a high estimate of 78.00 and a low estimate of 77.70.
EPS
Institutional Holdings
Institutions: 213
Institutional Holdings: 21.47M
% Owned: 12.94%
Shares Outstanding: 165.87M
TypeInstitutionsShares
Increased
52
1.17M
New
23
415.02K
Decreased
48
1.17M
Sold Out
21
250.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.17%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Director
Satish Reddy
Co-Chairman/Managing Director/Director
G. Prasad
Chief Executive Officer
Erez Israeli
Chief Financial Officer
Parag Agarwal
Corporate Executive
Patrick Aghanian
Corporate Executive
Marc Kikuchi
Corporate Executive
M. Ramana
Chief Human Resource Officer
Archana Bhaskar
Chief Information Officer
Mukesh Rathi
Other
Raymond De Vre
Other
Sauri Gudlavalleti
Other
Anil Namboodiripad
Other
Deepak Sapra
Other
Sanjay Sharma
Other
P. Yugandhar
Secretary
Sandeep Poddar
Non-Executive Independent Director
Bruce Carter
Non-Executive Independent Director
Bharat Doshi
Non-Executive Independent Director
Sridar Iyengar
Non-Executive Independent Director
Prasad Menon
Non-Executive Independent Director
Kalpana Morparia
Non-Executive Independent Director
Allan Oberman
Non-Executive Independent Director
Leo Puri
Non-Executive Independent Director
Shikha Sharma
Declaration Date
Dividend Per Share
Ex-Div Date
06/16/2021
Dividend USD 0.2797405
07/08/2021
06/26/2020
Dividend USD 0.2769603
07/10/2020
--
Dividend USD 0.262229
07/12/2019
--
Dividend USD 0.272
07/13/2018
08/04/2017
Dividend USD 0.294
07/13/2017
08/03/2016
Dividend USD 0.279
07/14/2016
08/11/2015
Dividend USD 0.293
07/08/2015
08/08/2014
Dividend USD 0.272
08/01/2014
--
Dividend USD 0.283
07/09/2014
08/08/2013
Dividend USD 0.225
07/10/2013
  • All
  • Financials
  • Insiders
More
About RDY
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Webull offers kinds of Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.